317-34-0
Chemical Structure
Aminophylline
- CAS No.: 317-34-0
- Formula:C7H8N4O2·1/2C2H8N2
- Molecular Weight:210.22
IUPAC Name: 1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione compound with ethane-1,2-diamine (2:1)
SMILES: O=C(N1C)N(C)C2=C(N=CN2)C1=O.NCCN.[1/2]
Biological Activity: Aminophylline is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline also acts as an adenosine receptor antagonist. Aminophylline elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes adenosine A1 receptor (ADORA1), regulates intracellular calcium signaling and synaptic vesicle cycling, upregulates the PPAR signaling pathway, and downregulates glutamatergic synaptic pathways simultaneously. Aminophylline can be used in research related to major depressive disorder, epilepsy, asthma, and chronic obstructive pulmonary disease (COPD)[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Aminophylline | 99.68% | Aminophylline is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline also acts as an adenosine receptor antagonist. Aminophylline elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes adenosine A1 receptor (ADORA1), regulates intracellular calcium signaling and synaptic vesicle cycling, upregulates the PPAR signaling pathway, and downregulates glutamatergic synaptic pathways simultaneously. Aminophylline can be used in research related to major depressive disorder, epilepsy, asthma, and chronic obstructive pulmonary disease (COPD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aminophylline (Standard) | ≥98% | Aminophylline (Standard) is the analytical standard of Aminophylline (HY-B0140). This product is intended for research and analytical applications. Aminophylline is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline also acts as an adenosine receptor antagonist. Aminophylline elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes adenosine A1 receptor (ADORA1), regulates intracellular calcium signaling and synaptic vesicle cycling, upregulates the PPAR signaling pathway, and downregulates glutamatergic synaptic pathways simultaneously. Aminophylline can be used in research related to major depressive disorder, epilepsy, asthma, and chronic obstructive pulmonary disease (COPD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Samante FI, et al. Potential antidepressant properties of aminophylline in male mice exposed to chronic restraint stress. Pharmacological reports : PR. 2026 Jun;78(3):748-761. [Content Brief]
- [2]. Czuczwar SJ, et al. Effect of aminophylline on the protective action of common antiepileptic drugs against electroconvulsions in mice. Epilepsia. 1986;27(3):204-8. [Content Brief]
- [3]. Mengozzi G, et al. Comparative bioavailability of two sustained-release theophylline formulations in the dog. Pharmacological research. 1998 Dec;38(6):481-5. [Content Brief]
- [4]. Aubier M, et al. Aminophylline improves diaphragmatic contractility. The New England journal of medicine. 1981 Jul 30;305(5):249-52.
- [5]. Marrack P, et al. The staphylococcal enterotoxins and their relatives. Science (New York, N.Y.). 1990 May 11;248(4956):705-11.
- [6]. Suneby Jagers JV, et al. Aminophylline increases parasternal muscle action in awake canines. Pulmonary pharmacology & therapeutics. 2019 Jun;56:1-7.
